Batoclimab 680 mg SC weekly + Batoclimab 340 mg SC weekly + Matching Placebo SC + Batoclimab 340 mg SC bi-weekly
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Myasthenia Gravis
Conditions
Generalized Myasthenia Gravis
Trial Timeline
Jun 27, 2022 → Jan 1, 2027
NCT ID
NCT05403541About Batoclimab 680 mg SC weekly + Batoclimab 340 mg SC weekly + Matching Placebo SC + Batoclimab 340 mg SC bi-weekly
Batoclimab 680 mg SC weekly + Batoclimab 340 mg SC weekly + Matching Placebo SC + Batoclimab 340 mg SC bi-weekly is a phase 3 stage product being developed by Immunovant for Generalized Myasthenia Gravis. The current trial status is active. This product is registered under clinical trial identifier NCT05403541. Target conditions include Generalized Myasthenia Gravis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05403541 | Phase 3 | Active |
Competing Products
20 competing products in Generalized Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Ixekizumab | Eli Lilly | Approved | 85 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 52 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 85 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 52 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 52 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 33 |
| Escitalopram | AbbVie | Approved | 85 |
| Adalimumab | AbbVie | Phase 3 | 77 |